Drug Trial Radar · NCT02804763
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Jun 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Jun 2, 2016
Primary completion
May 31, 2018
Study completion Nov 19, 2018
Sponsor
- Lead sponsor
- UCB Biopharma S.P.R.L.UCB
- Sponsor type
- Industry
- First posted
- Jun 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
Conditions
- Systemic Lupus Erythematosus (SLE)
Interventions
PlaceboDrug
Solution for infusion, 0,9% saline
Dapirolizumab pegol (DZP)Drug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 24Time frame: Week 24
Locations
71 sites in 13 countries. Site status is shown where the registry gives one.
Sl0023 312
Birmingham, Alabama
Sl0023 307
El Cajon, California
Sl0023 309
El Cajon, California
Sl0023 323
Huntington Beach, California
Sl0023 311
Los Angeles, California
Sl0023 314
Thousand Oaks, California
Sl0023 302
Upland, California
Sl0023 326
New Haven, Connecticut
Sl0023 304
Clearwater, Florida
Sl0023 322
DeBary, Florida
Sl0023 321
Miami, Florida
Sl0023 301
Miami Lakes, Florida
Sl0023 319
Palm Harbor, Florida
Sl0023 310
Tampa, Florida
Sl0023 324
Atlanta, Georgia
Sl0023 327
Stockbridge, Georgia
Sl0023 320
Idaho Falls, Idaho
Sl0023 306
Albuquerque, New Mexico
Sl0023 313
Lake Success, New York
Sl0023 305
Oklahoma City, Oklahoma
Sl0023 315
Jackson, Tennessee
Sl0023 308
Memphis, Tennessee
Sl0023 317
Amarillo, Texas
Sl0023 303
Houston, Texas
Sl0023 328
Spokane, Washington
Sl0023 101
Plovdiv, Bulgaria
Sl0023 102
Plovdiv, Bulgaria
Sl0023 202
Providencia, Chile
Sl0023 203
Providencia, Chile
Sl0023 201
Puerto Varas, Chile
Sl0023 204
Viña del Mar, Chile
Sl0023 213
Barranquilla, Colombia
Sl0023 212
Bogotá, Colombia
Sl0023 214
Bogotá, Colombia
Sl0023 216
Bucaramanga, Colombia
Sl0023 211
Chía, Colombia
Sl0023 215
Medellín, Colombia
Sl0023 341
Hanover, Germany
Sl0023 113
Leipzig, Germany
Sl0023 124
Debrecen, Hungary
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.